Valproic acid-induced hyperammonemia in a patient with schizoaffective disorder

Journal of Pharmacy Practice

Volumn 20, Issue 1, 2007, Pages 82-92

  Ott, Carol A ^a,b   Campbell, Noll ^b   Dworek, Elayne A ^a,c  

^a PURDUE UNIVERSITY   (United States)

^b WISHARD HEALTH SERVICES   (United States)

^c INDIANA UNIVERSITY HEALTH   (United States)

Author keywords

Carnitine; Hyperammonemia; Lactulose; Naloxone; Schizoaffective disorder; Urea cycle; Valproic acid

Indexed keywords

LIVER ENZYME; VALPROIC ACID;

ADULT; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ENZYME ASSAY; HUMAN; HYPERAMMONEMIA; MALE; SCHIZOAFFECTIVE PSYCHOSIS;

EID: 34547399095     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190007303054     Document Type: Article

References (42)

1. Coulter DL, Allen R. Hyperammonemia with valproic acid therapy. J Pediatr. 1981 ; 99: 317-319.
2. Rawat S., Borkowski W., Swick H. Valproic acid and secondary hyperammonemia. Neurology. 1981 ; 31: 1173-1174.
3. Zaret BS, Beckner RR, Marini AM, Wagle W., Passerelli C. Sodium valproate-induced hyperammonemia without clinical hepatic dysfunction. Neurology. 1982 ; 32 (2). 206-208.
4. Weng TI, Shin FF, Chen WJ Unusual causes of hyperammonemia in the ED. Am J Emer Med. 2004 ; 22 (2). 105-107.
5. Kimmel R., Irwin S., Meyer JM Valproic acid-associated hyperammonemic encephalopathy: a case report from the psychiatric setting. Int Clin Psychopharmacol. 2005 ; 20 (1). 57-58.
6. Elgudin L., Hall Y., Schubert G. Ammonia induced encephalopathy from valproic acid in a bipolar patient: a case report. Int J Psychiatr Med. 2003 ; 33 (1). 91-96.
7. McCall M., Bourgeois JA Valproic acid induced hyperammonemia: a case report. J Clin Psychopharmacol. 2004 ; 24 (5). 521-526.
8. Feil D., Chuang K., Sultzer DL Valproate-induced hyperammonemia as a cause of altered mental status. Am J Geriatr Psychiatry. 2002 ; 10 (4). 476-478.
9. Eze E., Workman M., Donley B. Hyperammonemia and coma developed by a woman treated with valproic acid for affective disorder. Psychiatr Serv. 1998 ; 49 (10). 1358-1359.
10. Barrueto F., Hack J. Hyperammonemia and coma without hepatic dysfunction induced by valproate therapy. Acad Emerg Med. 2001 ; 8 (10). 999-1001.
11. Yehya N., Saldarini CT, Koski ME, Davanzo P. Valproate-induced hyperammonemic encephalopathy. J Am Acad Child Adolesc Psychiatry. 2004 ; 43 (8). 926-927.
12. Mallet L., Babin S., Morais JA Valproic acid-induced hyperammonemia and thrombocytopenia in an elderly woman. Ann Pharmacother. 2004 ; 38: 1643-1647.
13. Stewart JT Treatment of valproate-induced hyperammonemia. J Am Geriatr Soc. 2005 ; 53 (6). 1080.
14. Panikkar GP, Gilman SM Valproate-induced hyperammonemia in the psychiatric setting: 2 cases. J Clin Psychiatry. 1999 ; 60 (8). 557-559.
15. Settle EC Valproic acid-associated encephalopathy with coma. Am J Psychiatry. 1995 ; 152 (8). 1236-1237.
16. Hamer HM, Knake S., Schomburg U., Rosenow F. Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology. 2000 ; 54 (1). 230-232.
17. Depakote® ER Package Insert. North Chicago, IL: Abbott Laboratories, Inc ; 2004, September.
18. Spina E., Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord. 2004 ; 6 (2). 57-75.
19. Tariot PN Valproate use in neuropsychiatric disorders in the elderly. Psychopharmacol Bull. 2003 ; 37 (suppl 2). 116-128.
20. Zanarini MC Update on pharmacotherapy of borderline personality disorder. Curr Psychiatry Rep. 2004 ; 6 (1). 66-70.
21. Myrick H., Brady KT The use of divalproex in the treatment of addictive disorders. Psychopharmacol Bull. 2003 ; 37 (suppl 2). 89-97.
22. Sztajnkrycer MD Valproic acid toxicity: overview and management. J Toxicol Clin Toxicol. 2002 ; 40 (6). 789-801.
23. Naranjo CA, Busto U., Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981 ; 30 (2). 239-245.
24. Eyer F., Felgenhauer N., Gempel K., Steimer W., Gerbitz KD, Zilker T. Acute valproate poisoning: pharmacokinetics, alteration in fatty acid metabolism, and changes during therapy. J Clin Psychopharmacol. 2005 ; 25 (4). 376-380.
25. Moreno FA, Macey H., Schreiber B. Carnitine levels in valproic acid-treated psychiatric patients: a cross-sectional study. J Clin Psychiatry. 2005 ; 66 (5). 555-558.
26. Raskind JY, El-Chaar GM The role of carnitine supplementation during valproic acid therapy. Ann Pharmacother. 2000 ; 34 (5). 630-638.
27. Topamax® Package Insert. Titusville, NJ: Ortho-McNeil Neurologics, Inc ; 2005, June.
28. Fraser CM, Sills GJ, Forrest G., Thompson GG, Brodie MJ Effects of antiepileptic drugs on glutamine synthetase activity in mouse brain. Br J Pharmacol. 1999 ; 126: 1634-1638.
29. Monfort P., Kosenko E., Erceg S., et al. Molecular mechanism of acute ammonia toxicity: role of NMDA receptors. Neurochem Int. 2002 ; 41: 95-102.
30. Cooper AJ Role of glutamine in cerebral nitrogen metabolism and ammonia neurotoxicity. Ment Retard Dev Disabil Res Rev. 2001 ; 7: 280-286.
31. Hertz L., Yu Ach, Kala G., Schousboe A. Neuronal-astrocytic and cytosolic-mitochondrial metabolite trafficking during brain activation, hyperammonemia, and energy deprivation. Neurochem Int. 2000 ; 37: 83-102.
32. Marcaida G., Felipo V., Hermenegildo C., Minana MD, Grisola S. Acute ammonia toxicity is mediated by the NMDA type of glutamate receptors. FEBS Lett. 1992 ; 13 (296). 67-68.
33. Prietsch V., Lindner M., Zschocke J., et al. Emergency management of inherited metabolic diseases. J Inherit Metab Dis. 2002 ; 25: 531-546.
34. Gidal BE, Garnett WR Epilepsy. In: DiPiro JT, ed. Pharmacotherapy: A Pathophysiologic Approach. 6 th ed. New York: McGraw-Hill ; 2005: 1023-1048.
35. Ammonul® package insert. Phoenix, AZ: Watson Laboratories, Inc ; 2005, October.
36. Hoover JE Gastrointestinal and liver drugs. In: Troy DB, ed. Remington: The Science and Practice of Pharmacy. 21 st ed. Baltimore, MD: Lippincott Williams & Wilkins ; 2005: 1294-1317.
37. Houghton BL, Bowers JB Valproic acid overdose: a case report and review of therapy. Med Gen Med. 2003 ; 5 (1). 5.
38. Roberge RJ, Francis EH 3rd. Use of naloxone in valproic acid overdose: case report and review. J Emerg Med. 2002 ; 22 (1). 67-70.
39. Montero FJ Naloxone in the reversal of coma induced by sodium valproate. Ann Emerg Med. 1999 ; 33 (3). 357-358.
40. Alberto G., Erickson T., Popiel R., Narayanan M., Hryhorczuk D. Central nervous system manifestations of a valproic acid overdose responsive to naloxone. Ann Emerg Med. 1989 ; 18 (8). 889-891.
41. Hicks LK, McFarlane PA Valproic acid overdose and haemodialysis. Nephrol Dial Transplant. 2001 ; 16 (7). 1483-1486.
42. Clark WR, Hamburger RJ, Lysaght M. Effect of membrane composition and structure on solute removal and biocompatibility in hemodialysis. Kidney Int. 1999 ; 56: 2005-2015.